v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04412057 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : March 4, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : March 4, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
jwilkins@cerecor.com |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-06-02 |
Recruitment status
Last imported at : March 4, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : March 27, 2022, 4 p.m. Source : ClinicalTrials.gov |
inclusion criteria: subject/legally authorized representative (lar) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study. subject is ≥18 years of age at the time of informed consent and assent (as applicable). subject is male or non-pregnant, non-lactating female, who if of childbearing potential agrees to comply with any applicable contraceptive requirements if. discharged from the hospital prior to completing the study. subject has a diagnosis of covid-19 infection through an approved testing method. subject has been hospitalized due to clinical diagnosis of pneumonia with acute lung injury defined as diffuse bilateral radiographic infiltrates with partial pressure of arterial oxygen/percentage of inspired oxygen (pao2/fio2) >100 and <300. subject's oxygen saturation at rest in ambient air <93% |
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
subject is intubated. subject is currently taking immunomodulators or anti-rejection drugs. subject has been administered an immunomodulating biologic drug within 60 days of baseline. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit. |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Aevi Genomic Medicine, LLC, a Cerecor company |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
100 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
United States |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Severe disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
6: Severe disease at enrollment |
Total sample size
Last imported at : March 5, 2022, 9:30 p.m. Source : ClinicalTrials.gov |
88 |
primary outcome
Last imported at : March 27, 2022, 4 p.m. Source : ClinicalTrials.gov |
Number of Subjects Alive and Free of Respiratory Failure |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 265, "treatment_name": "Cerc-002", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |